Cassiopea Wins With Winlevi Acne Phase III Data

Shares in Italy's Cassiopea SPA have soared on the back of impressive top-line late-stage data which suggests that Winlevi (clascoterone) could provide the first new mechanism for the treatment of acne for decades.

Cassiopea, which was spun out of Cosmo Pharmaceuticals NV as a pure-play dermatology company in 2015 and is listed in Switzerland, heralded what it called "very positive results" from two Phase III trials of Winlevi, which could become the first topical anti-androgen drug to be approved